SLC5A2 and chronic kidney disease: Although SGLT-2 inhibitors have demonstrated significant efficacy and broad potential in diabetic and non-diabetic CKD patients, their use requires careful management of potential side effects, such as urinary tract infections, hypotension, and diabetic ketoacidosis [113].